UPCC 07217: A Phase 1/2 Open-Label Dose-Escalation Safety Tolerability and Efficacy Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207)

UPCC 07217: A Phase 1/2 Open-Label Dose-Escalation Safety Tolerability and Efficacy Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207)
99 years or below
All
Phase 2
1 Location

Brief description of study

Request for collaborative review: CGIRB serving as IRB of record.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: TBD, tbd, tbd
  • Age: 99 years or below
  • Gender: All
Updated on 27 Aug 2018. Study ID: 827088

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.